At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NKGN NKGEN BIOTECH INC
Market Closed 12-20 16:00:00 EST
0.6400
+0.0749
+13.25%
盘后0.6400
+0.00000.00%
19:59 EST
High0.6547Low0.5558Vol443.15K
Open0.5840D1 Closing0.5651Amplitude17.50%
Mkt Cap22.63MTradable Cap10.31MTotal Shares35.36M
T/O266.66KT/O Rate2.75%Tradable Shares16.11M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Nkgen Biotech Selected As Preferred Stalking Horse Bidder For Nkmax Co.
Reuters  ·  12-03
BRIEF-Nkgen Biotech Selected As Preferred Stalking Horse Bidder For Nkmax Co.
NKGen Biotech: Selected as Preferred Stalking Horse Bidder for Nkmax Co., in Nkmax's Court-Managed Rehabilitation Process in South Korea
THOMSON REUTERS  ·  12-03
NKGen Biotech: Selected as Preferred Stalking Horse Bidder for Nkmax Co., in Nkmax's Court-Managed Rehabilitation Process in South Korea
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
GlobeNewswire  ·  12-03
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
NKGen Biotech gets Nasdaq notice related to delayed quarterly report
TIPRANKS  ·  11-27
NKGen Biotech gets Nasdaq notice related to delayed quarterly report
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
THOMSON REUTERS  ·  11-27
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
BRIEF-Nkgen Biotech Inc On Nov 5, As Part Of Cost-Reduction Efforts, Conducted A Group Layoff Of 16 Employees.
Reuters  ·  11-13
BRIEF-Nkgen Biotech Inc On Nov 5, As Part Of Cost-Reduction Efforts, Conducted A Group Layoff Of 16 Employees.
NKGen Biotech Inc: on Nov 5, as Part of \Greater Cost-Reduction Efforts, Conducted a Group Layoff of 16 Employees.
THOMSON REUTERS  ·  11-13
NKGen Biotech Inc: on Nov 5, as Part of \Greater Cost-Reduction Efforts, Conducted a Group Layoff of 16 Employees.
BRIEF-Nkgen Biotech Says Co Placed 19 Employees On Furlough
Reuters  ·  10-31
BRIEF-Nkgen Biotech Says Co Placed 19 Employees On Furlough
NKGen Biotech - Co's Inability to Pay Its Payroll Obligations May Result in Employees Terminating Relationship With Co and/or Pursuing Legal Remedies
THOMSON REUTERS  ·  10-31
NKGen Biotech - Co's Inability to Pay Its Payroll Obligations May Result in Employees Terminating Relationship With Co and/or Pursuing Legal Remedies
NKGen Biotech Inc - on Oct 24, Co Placed 19 Employees on Furlough, Effective October 27
THOMSON REUTERS  ·  10-31
NKGen Biotech Inc - on Oct 24, Co Placed 19 Employees on Furlough, Effective October 27
NKGen Biotech announces presentation of two posters in AD
TIPRANKS  ·  10-29
NKGen Biotech announces presentation of two posters in AD
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
THOMSON REUTERS  ·  10-29
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire  ·  10-29
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech Announces Poster Presentations at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
THOMSON REUTERS  ·  10-08
NKGen Biotech Announces Poster Presentations at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire  ·  10-08
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
BRIEF-Nkgen Biotech Size Of Board Temporarily Reduced From Five To Two Directors
Reuters  ·  10-04
BRIEF-Nkgen Biotech Size Of Board Temporarily Reduced From Five To Two Directors
NKGen Biotech: Size of Each Committee Is Temporarily Reduced From Three to One Member
THOMSON REUTERS  ·  10-04
NKGen Biotech: Size of Each Committee Is Temporarily Reduced From Three to One Member
BRIEF-NKGen Biotech Receives Deficiency Letter From Nasdaq
Reuters  ·  09-28
BRIEF-NKGen Biotech Receives Deficiency Letter From Nasdaq
NKGen Biotech Inc -on Sept 23, Got Deficiency Letter From Nasdaq on Co's Failure to Satisfy a Continued Listing Rule or Standard
THOMSON REUTERS  ·  09-28
NKGen Biotech Inc -on Sept 23, Got Deficiency Letter From Nasdaq on Co's Failure to Satisfy a Continued Listing Rule or Standard
NKGen Biotech Inc - No Drug-Related Adverse Reactions in Phase 1 Cohort After 3 Months
THOMSON REUTERS  ·  09-12
NKGen Biotech Inc - No Drug-Related Adverse Reactions in Phase 1 Cohort After 3 Months

Introduction

Company Name.
NKGEN BIOTECH INC
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
Issue price:
--